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ABSTRACT 
Previous studies have shown that the skeletal dihydropydidine receptor (DHPR) pore subunit 
CaV1.1 (α1S) physically interacts with ryanodine receptor type 1 (RyR1) and a molecular signal is 
transmitted from α1S to RyR1 to trigger excitation-contraction (EC) coupling. We show that the β 
subunit of the skeletal DHPR also binds RyR1 and participates in this signaling process. A novel 
binding site for the DHPR β1a subunit was mapped to the M3201 to W3661 region of RyR1. In-vitro 
binding experiments showed that the strength of the interaction is controlled by K3495KKRR_ _R3502, a 
cluster of positively charged residues. Phenotypic expression of skeletal-type EC coupling by RyR1 with 
mutations in the K3495KKRR_ _R3502 cluster was evaluated in dyspedic myotubes. The results indicated 
that charge neutralization or deletion severely depressed the magnitude of RyR1-mediated Ca2+ 
transients coupled to voltage-dependent activation of the DHPR. Meantime the Ca2+ content of the 
sarcoplasmic reticulum, was not affected and the amplitude and activation kinetics of the DHPR Ca2+ 
currents were slightly affected. The data show that the DHPR β subunit, like α1S, interacts directly with 
RyR1 and is critical for the generation of high-speed Ca2+ signals coupled to membrane depolarization. 
These findings indicate that EC coupling in skeletal muscle involves the interplay of at least two 
subunits of the DHPR, namely α1S and β1a, interacting with possibly different domains of RyR1.  
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INTRODUCTION 
Skeletal muscle cells respond to membrane action potentials with an elevation in cytosolic Ca2+ 
that develops rapidly and is a graded function of voltage. The mechanism that couples muscle 
membrane excitation to the cytosolic Ca2+ increase, also known as excitation-contraction (EC) 
coupling, is made possible by the strict functional and structural relationship of the DHPR and RyR1 
(1). Direct or indirect physical contact between these two Ca2+ channels are thought to ensure that 
charge movements in the DHPR are transduced at high-speed into a conformational change that opens 
the RyR1 channel leading to a massive release of Ca2+ from the sarcoplasmic reticulum. Multiple 
approaches have suggested that the cytosolic loop linking repeats II and III of α1S binds RyR1 and/or 
is responsible for the conformational change that opens the RyR1 channel (2-10). However, α1S 
domains outside the II-III loop also bind RyR1 (11) and furthermore, the functional recovery produced 
by the II-III loop, in the absence of other skeletal domains, is incomplete (12). Thus, despite the 
structural and functional significance of the II-III loop, other molecular determinants may influence 
coupling between the skeletal DHPR and RyR1.   
The pore subunit of the DHPR is tightly bound to a β subunit that modulates multiple processes 
ranging from the voltage-dependence of the gating current to trafficking of the Ca2+ channel to the 
plasma membrane (13-16). Inactivation of the β1 gene in skeletal muscle led to a decrease in α1 subunit 
expression and the elimination of EC coupling (17). However, β1a and α1S coexpression experiments in 
dysgenic myotubes (lacking α1S) have shown that EC coupling could be observed in the absence of β1a 
(18). The common experience gained from heterologous expression systems has been that β subunits 
from different tissues are highly interchangeable among Ca2+ channels (13). In skeletal myotubes, 
several non-muscle β variants can be integrated into an otherwise skeletal DHPR to generate Ca2+ 
currents, but the EC coupling function specifically requires the endogenous variant β1a (19). A unique 
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heptad repeat in the C-terminus of β1a, unrelated to membrane trafficking, was found to be essential for 
skeletal-type EC coupling (19). The latter observation raises the question of whether the β1a subunit 
binds RyR1 and in this way directly influences EC coupling. Recent crystallographic studies show that 
the common core of the β subunit consists of a tandem of two protein modules, an N-terminal SH3 (Src 
homology region 3) domain and a C-terminal GK (guanylate kinase) domain (20,21). The studies further 
show that the GK module interacts with α1, whereas the SH3 module found in many protein-protein 
interactions, is exposed to the cytosol (20). Bearing in mind this topology and the tight coupling that 
exists between the cytosolic faces of the DHPR and RyR1, an interaction of β1a with RyR1 seems 
likely. The same conclusion can be reached from models depicting the arrangement of the skeletal 
DHPR over the foot structure of RyR1 (22,23). In the present paper, we mapped a binding domain in 
RyR1 for the skeletal DHPR β1a subunit and described the EC coupling phenotype of mutations in 
RyR1 that disrupt binding of the β subunit. Part of this data has been previously presented in abstract 
form (24).  
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MATERIALS AND METHODS 
 
RyR1 mutations. A pCI-neo vector (Promega, Madison, WI) with a full-length RyR1 insert (Genbank 
X15209) was kindly provided by P.D. Allen. To generate mutations in full-length RyR1, the NdeI (nt 
387) and NheI (nt 1085) sites on the pCI-neo vector were destroyed and unique silent EcoRV and NheI 
cloning sites were respectively introduced at nucleotide positions 9726 and 10014. KtoQ and ΔKtoR 
mutations described in the text were generated by 3-step PCR (four primers and three reactions). The 
PCR products were subcloned into a pCR2.1 vector (Invitrogen, Carlsbad, CA) and inserted into full 
length RyR1 via unique NheI and NdeI sites. 
 
Recombinant proteins. The GST (glutathione-S-transferase)-his vector was generated by inserting six 
histidines in tandem into a pGEX-2T vector (Amersham Pharmacia, Piscataway, NJ) by PCR via unique 
BstBI and EcoRI sites. The GST-β1a-his vector was generated by inserting the β1a cDNA (Genbank 
NM_031173) into the GST-his vector via unique BamHI and EcoRI sites. Transformed BL21(DE3) 
bacterial cells were grown at 37°C and induced with 0.4 mM IPTG  (isopropyl-β-D-
thiogalactopyranoside). Cells were spun, resuspended in phosphate-buffered saline (PBS) containing 20 
mM imidazole with protease inhibitors, and briefly sonicated on ice using a Branson Sonifier 250 
(Branson Ultrasonics, Danbury, CT). Triton X-100 (Sigma, St. Louis, MO) was adjusted to 1% at 4°C 
and the suspension was centrifuged at 11,000 g for 30 minutes. The supernatant was incubated with 0.5 
ml Ni-NTA agarose (Qiagen, Valencia, CA) for 1 hour at 4°C with gentle agitation. Ni-NTA agarose 
beads were packed into a poly-prep column (Bio-Rad, Hercules, CA), washed with PBS containing 20 
mM imidazole, and eluted with 3 ml of PBS containing 250 mM imidazole. The eluate was combined 
with 1 ml of a 50% slurry of glutathione sepharose (GS) 4B beads (Amersham Pharmacia, Piscataway, 
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NJ), incubated for 30 minutes at 4°C with gentle agitation, and washed with PBS. Sepharose beads 
covered with full length GST-β1a-his were then stored frozen. 
 
In-vitro translation and pull-down assays. With exception of the RyR1 fragment I cDNA, all other 
RyR1 fragment cDNAs tested in Fig. 1 were generated by PCR with primers containing EcoRI-BamHI, 
EcoRI-NotI, BamHI-NotI, or NheI-NotI restriction sites. PCR products were inserted into a T7-driven 
pSG5 vector (Stratagene, La Jolla, CA) via the unique restriction sites mentioned above. Fragment I 
cDNA was made by cutting the pCI-neo-RyR1 vector with XhoI, followed by self-ligation. Fragment G 
mutations tested in Fig. 2 were generated by PCR and inserted into the pCI-neo-RyR1 vector via 
EcoRV-NheI or NheI-NdeI sites. The 3201-3661 region bearing the mutation of interest was amplified 
by PCR and inserted into a T7-driven pSG5 vector via EcoRI and BamHI sites for in-vitro translation.  
RyR1 protein fragments were generated in a TNT T7 reticulocyte lysate system (Promega, Madison, 
WI) with the incorporation of S35-Methionine (Amersham Pharmacia, Piscataway, NJ) as described by 
manufacturers. For pull-down of in-vitro transcribed RyR1 fragments, 100 μl of the GS bead/GST-β-his 
mixture (~ 200 pmoles of recombinant GST-β-his protein) were incubated with 30 μl of in-vitro 
translated RyR1 fragment (~ 30 fmoles) in 1 ml of binding buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 
1 mM MgCl2, 0.1 mM DTT, and 0.1 % CHAPS) at 4°C for 15 hours with agitation. Beads were washed 
extensively with binding buffer and mixed with 30 μl of SDS-PAGE loading buffer (100 mM Tris, pH 
6.8, 10% β-mercaptoethanol, 4% SDS, 0.2% bromophenol blue, and 20% glycerol) and boiled for 5 
minutes. For autoradiograms, 15% SDS-PAGE gels were air dried and exposed to Kodak X-Omat AR 
film (Eastman Kodak, Rochester, NY) for 4 hours at –80°C. Rabbit skeletal muscle RyR1 was purified 
as described (25). For pull-down of purified RyR1, 100 µl of the GS bead/GST-β mixture were 
incubated with 200 µl of purified RyR1 (~40 pmoles) in 150 mM NaCl, 2 mM EGTA, 2 mM CaCl2, 
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pCa5 and 20 mM HEPES, pH 7.4 at 4°C overnight. Beads were spun and washed extensively with the 
same buffer. Bound proteins were eluted with SDS-PAGE loading buffer and analyzed by 15% SDS-
PAGE. 
 
Primary cultures and cDNA transfection. Dyspedic mice founders were a gift of P.D. Allen.  
Primary cultures were prepared from enzyme-digested mouse hind limbs of dyspedic (RyR1 KO) 
embryos as described (26). The RyR1 cDNA of interest and a separate expression vector encoding the T 
cell membrane antigen CD8 were mixed and cotransfected with the polyamine LT-1 (Panvera, Madison, 
WI). Whole-cell recordings were made 3-5 days after transfection. Cotransfected cells were recognized 
by incubation with CD8 antibody beads (Dynal, Oslo, Norway).  
 
Whole-cell voltage clamp. Myotubes were whole-cell clamped with an Axopatch 200B (Axon 
Instruments, Foster City, CA) amplifier as described (19). The external solution was (in mM) 
130 tetraethylammonium-methanesulfonate, 10 CaCl2, 1 MgCl2, 10 Hepes-tetraethylammonium(OH), 
pH 7.4. The pipette solution was (in mM) 140 Cs-aspartate, 5 MgCl2, 0.1 EGTA (for Ca2+ transients) or 
5 EGTA (for Ca2+ currents), 10 4-morpholinepropanesulfonic acid-CsOH (pH 7.2).  
 
Confocal fluorescence microscopy. Cells loaded with 4 µM fluo-4 acetoxymethyl ester (Molecular 
Probes, Eugene, OR) for 30 minutes at room temperature as described (19). Cells were viewed with an 
inverted Olympus microscope with a 20 X objective (N.A. = 0.4) and a Fluoview confocal attachment 
(Olympus, New Hyde Park, NY). Excitation light was provided by a 5-mW argon laser attenuated to 6% 
with neutral density filters. Line scans images were taken at a speed of 2.05 ms per line (512 pixels per 
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line) and integrated along the cell dimension to obtain the space-averaged time course of the 
cytoplasmic Ca2+ transient. 
 
Curve fitting. The voltage dependence of peak intracellular Ca2+ (ΔF/F), and Ca2+ conductance (G) was 
fit with the Boltzmann equation, A = [Amax]/[1 + exp((Vm - V1/2)/k)], where Amax is ΔF/Fmax or 
Gmax; Vm is the membrane potential, V1/2 is the potential at which A = Amax/2; and k is the slope 
factor. Ca2+ transient kinetics were analyzed at +30 mV (in the absence of Cd2+) using transforms 
“CBESPLN1.XFM” and “CBESPLN2.XFM” in “Sigmaplot”. These transforms take “time and ΔF/F” 
data sets with increasing ordered time values (in ms) and compute the cubic spline interpolation. The 
first and second derivatives of the spline are also computed. 
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RESULTS 
Prompted by structure-function studies linking the DHPR β1a subunit to the mechanism of 
skeletal-type EC coupling (19), we searched for a binding site for β1a in RyR1. Recombinant β1a pre-
bound to GS beads was used to pull-down in-vitro expressed S35-methionine labeled RyR1 fragments of 
~500 residues, which is a fragment size comparable to that of full-length β1a (Fig. 1A). Recombinant 
GST-β1a-his fusion protein was purified on Ni-NTA agarose and GS. The presence of GST and his tag 
on N-terminus and C-terminus of β1a respectively allowed the enrichment of full-length protein during 
purification. Purified GST-β1a-his fusion had the appropriate mobility on SDS-PAGE (Fig. 1B), and the 
estimated purity was >85% based on densitometry. Pull-downs were performed in a >1000-fold molar 
excess of recombinant β protein relative to in-vitro translated RyR1 fragment. Saturation of the 
efficiency of the pull-down was confirmed by serial dilution of the GS/GST-β1a-his beads (not shown). 
All RyR1 fragments, except H, were expressed essentially as single polypeptides with minor 
degradation (Fig. 1C). Fragments were incubated with purified GST-his or GST-β1a-his pre-bound to 
GS and pulled-down essentially as described (27). GST-β1a-his showed strong binding to RyR1 
fragment G (M3201 to W3661). Controls with GST-his lacking the insert indicated that pull-down did not 
occur in the absence of β1a. We further optimized the assay by testing several overlapping fragments in 
the F-G-H region (Fig. 1D). The results indicated that the 3201-3661 region covered by fragment G had 
the strongest binding and that the N- and C-terminal halves of the G region needed to be present in the 
same fragment for binding to occur, i.e., we found noticeably weak pull-down of fragment FG’’ and 
GH’ (Fig. 1D). To validate the pull-down experiments, the purified recombinant GST-β1a-his protein 
was subjected to several controls described elsewhere (24). GS/GST-β1a-his beads efficiently pulled-
down in-vitro translated α1S I-II loop (α1S G335-R432), the α1 domain that binds the β subunit (28). In 
addition, a recombinant β1a lacking the so-called BID region required for I-II loop binding, namely β1a 
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Δ(I278-Y287), was unable to pull-down the I-II loop but interaction with fragment G was unaffected. 
Finally, Fig. 1E demonstrated the ability of GS/GST-β1a-his beads to efficiently pull-down RyR1 
purified from rabbit skeletal muscle sarcoplasmic reticulum, demonstrating the ability of the 
recombinant fusion protein to interact with a RyR1 tetramer.  
 
Residues of RyR1 with a high impact on β1a binding were identified by examining structural 
motifs in the G region (see Fig. 2A). Fig. 2B shows that elimination of a poly-proline stretch (P3292-
P3303), a common binding partner for SH3 domains (29), or of an R3499G3500D3501 motif (not shown), a 
common cell adhesion motif that binds to extracellular matrix protein integrins (30), did not affect the 
ability of GST-β1a-his to pull-down the mutated fragment G. We further tested deletions of 25 to 34 
residues to eliminate predicted secondary structures. With this approach we found that deletion of 
residues D3490-N3523 (labeled 4), but not the flanking regions, significantly weakened β1a binding to 
fragment G. The most salient feature of the stretch eliminated by this deletion is a cluster of six positive 
charges, K3495KKRR_ _ R3502, concentrated near the N-terminal end of the deleted region. Fig. 2B 
shows that neutralization of the charges in the cluster (labeled KtoQ) or deletion of the first 5 charges 
(labeled ΔKtoR) significantly reduced the ability of the mutated fragment G to interact with β1a (see 
arrows and Fig. 2 legend for details).  
Mutations affecting β1a binding were introduced in an otherwise full-length RyR1 and the 
changes in the EC coupling phenotype investigated by cDNA expression in dyspedic myotubes (31). 
DHPR Ca2+ current density depends on RyR1 expression via a mechanism that requires physical 
coupling of the RyR1 to the DHPR, the so-called retrograde coupling (31,32). Hence, it was important to 
determine whether the RyR1 mutations affected Ca2+ current expression. We found that deletion of the 
34 residues comprising region 4 (RyR1 ΔD3490-N3523), substantially reduced DHPR Ca2+ current 
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expression (of 36 dyspedic myotubes expressing RyR1 ΔD3490-N3523 , 11 did not rescue current, and 25 
rescued small currents with mean Gmax of 62.5 pS/pF) preventing a clear analysis of the effect of this 
deletion on the depolarization induced Ca2+ release, i.e. the orthograde coupling between DHPR and 
RyR1. For this reason large deletions were not pursued further. In contrast, the two mutations in the 
K3495KKRR_ _ R3502 motif that were shown to weaken β-RyR1 interaction, preserved the expression of 
the DHPR Ca2+ current. Ca2+ currents expressed in the presence of wild-type RyR1 and RyR1 mutants 
with the neutralized (KtoQ) or deleted (ΔKtoR) cluster of charges are shown in Fig. 3. Ca2+ currents 
recovered by expression of either wild-type RyR1 or RyR1 KtoQ were typical of cultured skeletal 
myotubes (26) with a slow kinetics of activation, a peak current at ~+30 mV, and a maximum density 
that was entirely normal. In RyR1 ΔKtoR expressing cells, the slow kinetics of the Ca2+ current and the 
voltage-dependence were preserved but the maximum density decreased slightly (t-test significance 
p=0.015). Kinetic analysis of the DHPR Ca2+ currents expressed in the presence of RyR1 KtoQ or RyR1 
ΔKtoR shows that activation time constant of the fast component of the current was not significantly 
affected while the activation time constant of the slow component was slightly but significantly 
increased; τslow, 68.2 ± 5.3 ms, 85.4 ± 4.5 ms (p=0.024) and 95.7 ± 5.9 ms (p=0.002) and τfast , 9.8 ± 1.1 
ms, 11.5 ± 0.9 ms (p=0.271) and 12.8 ± 1.2 ms (p=0.085) for wild type RyR1, RyR1 KtoQ and RyR1 
ΔKtoR respectively. As indicated by the grey traces and symbols, Ca2+ currents were effectively blocked 
by 0.1 mM Cd2+ added to the bath solution, consistent with previous reports (6,12). These results show 
that neutralization, and to a lesser extent, deletion of the charges in the K3495KKRR_ _ R3502 cluster 
preserve DHPR-RyR1 retrograde coupling as manifested in DHPR Ca2+ current expression.  
Ca2+ transients elicited by depolarization of myotubes expressing wild type RyR1 and β binding-
deficient RyR1 are shown in Fig. 4. To determine SR Ca2+ content in transfected myotubes, we used the 
RyR1-specific agonist 4-chloro-m-cresol (4-CMC) (33). Cells were loaded with fluo-4 AM, and SR 
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Ca2+ release was induced by fast perfusion of external solution supplemented with 0.5 mM 4-CMC (Fig. 
4A). The time course of the space-averaged confocal fluorescence intensity was computed from the line-
scan image and is shown in ΔF/F units. The line diagrams mark the 4-second perfusion. A rapid increase 
in myotube fluorescence was observed in response to 4-CMC in RyR1-transfected but not in non-
transfected myotubes (dotted trace). Histograms of the mean maximum fluorescence induced by 4-CMC 
are shown in Fig. 4B. We found that Ca2+ release responses to 4-CMC were similar in all cases 
indicating that mutations in the K3495KKRR_ _ R3502 did not affect SR Ca2+ loading capacity of the 
myotubes. Fig. 4C shows Ca2+ transients elicited in RyR1 expressing myotubes under voltage-clamp. 
The line diagrams mark the 50-ms depolarization. In WT RyR1 expressing cells, cytosolic Ca2+ 
increased more rapidly than those in mutant RyR1 expressing cells during the depolarization. The peak 
Ca2+ during the transient was maximum at large positive potentials and the overall shape of the 
fluorescence vs. voltage curve was sigmoidal, rather than bell-shaped, in all cases (Fig. 4D), as expected 
for skeletal-type EC coupling. The main finding was that the KtoQ and ΔKtoR mutations significantly 
decrease the maximum amplitude of the Ca2+ transients (see legend). A derivative analysis indicated that 
the maximum Ca2+ transient release rates of myotubes expressing KtoQ and ΔKtoR mutants were 
significantly slower than that expressing RyR1 WT (p<0.001 for both cases, Fig. 4E). To confirm that 
the mutations preserved a bona fide skeletal-type Ca2+ release mechanism, experiments were repeated in 
external solution with 0.1 mM Cd2+ to block the Ca2+ current according to the results of Fig. 3. The 
results are shown in Fig. 4 C and D by the grey traces and symbols. As it can be seen, the amplitude of 
the Ca2+ transients and the voltage dependence of SR Ca2+ release were not changed. The results 
confirmed that depolarization induced Ca2+ transients observed with KtoQ and ΔKtoR RyR1 mutants 
were independent of DHPR Ca2+ current and therefore corresponded to a skeletal type EC coupling 
mechanism. 
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DISCUSSION 
 In this study we investigated the interaction of RyR1 calcium channel with the DHPR β1a 
subunit. We defined a unique domain of RyR1 encompassing the amino acids M3201 to W3661 as a β1a-
subunit binding domain. Neutralization or deletion of the charged amino acids within this RyR1 region, 
induced a loss of interaction with the β1a-subunit. Expression in dyspedic myotubes of RyR1 mutants 
carrying the mutations or deletion of the β1a-subunit binding domain led to the expression of DHPR 
Ca2+currents similar in density and voltage dependence but with a slightly modified kinetics compared 
to the current recorded in the presence of wild type RyR1. In contrast both amplitude and rate constant 
of the depolarization induced Ca2+ release were strongly reduced in myotubes expressing RyR1 KtoQ 
and RyR1 ΔKtoR. Therefore these results demonstrate for the first time that physical interaction 
between RyR1 and the β subunit of the DHPR plays an important role in the orthograde coupling 
between the two channels.  
 The β binding M3201-W3661 region of RyR1 was previously shown to house a calmodulin binding 
domain (34) as well as a binding site for both a 20-mer fragment of the II-III loop known as domain A 
and the toxin maurocalcine (35). Based on the 3-D reconstruction studies of RyR tetramer (34), this β-
binding region lies between morphological regions 3 and 4 that form a “handle-like” structure 
connecting the surface of the foot structure to the transmembrane pore-forming domains buried in the 
SR membrane. The β-binding region may thus be critical for funneling signals into the channel proper. 
We suggest that the β1a subunit when bound to region 3 and 4 may serve as a conduit for the 
conformational change transmitted to the RyR1 following DHPR charge movements. 
 Several studies have previously demonstrated the important role of the cytolpasmic II-III loop of 
the DHPR α1 subunit in the transmission of the information from the DHPR to the RyR1 (orthograde 
coupling) (2,36). Therefore β1a may amplify molecular signals produced by the II-III loop elsewhere in 
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the RyR1. Regardless of which of the two possibilities is more valid, i.e., whether β is a stand alone 
signaling element or is part of the molecular cascade of the II-III loop, the results suggest that the 
vicinity of the DHPR β binding site is a structurally sensitive part of the RyR1 channel and that the bulk 
of the EC coupling signal requires the interaction of β1a with RyR1.  
Grabner et al. (5) have shown that the motif of the II-III loop required for orthograde signal 
leading to the opening of RyR1 channel is also required for retrograde signal allowing the control of the 
DHPR Ca2+ channel by RyR1. Interestingly expression of RyR1 bearing KtoQ mutation in dipedic 
myotubes led to a normal density of DHPR Ca2+ current. Moreover RyR1 KtoQ and RyR1 ΔKtoR 
remain sensitive to the agonist 4-CMC and the sarcoplasmic reticulum of transfected myotubes retains 
the control of Ca2+ levels as determined by the in-situ release assay. Hence the low-level activity of the 
expressed RyR1, when cells are at rest, does not appear to be compromised. Finally, DHPR charge 
movements were not found to be altered by the aforementioned RyR1 mutations indicating that surface 
trafficking of endogenous DHPR is not altered (not shown) in agreement with the fact that the absence 
of RyR1 has only a small effect on DHPR charge movements (31,32). These results strongly suggest 
that the novel β1a–RyR1 interaction described here is mostly involved in the orthograde signal process. 
The proposed mechanisms of EC coupling have been influenced by models in which the outward 
movement of DHPR voltage sensors is coupled to Ca2+ release from the sarcoplasmic reticulum by 
mechanical torque exerted on the foot structure of RyR1 (37). A central role has been attributed to the 
α1S II-III loop in this mechanical coupling model. However, a molecular scenario in which the EC 
coupling signal is transmitted by single domain of the DHPR seems highly unlikely. The structural 
evidence, based on three-dimensional reconstruction of the purified DHPR complex, indicates that the 
area of potential contact between a DHPR α1S/β1a/γ1/α2-δ/ heterotetramer and a juxtaposed RyR1 
monomer, within the tetrameric foot structure, is exceedingly large (22,23). Hence, the number of 
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potential binding sites is large. The biochemical evidence indicates that the II-III loop, or sections 
thereof, interact with RyR1 sequences covered by fragments herein designated C (3), D (8), and/or the 
N-terminal third of G (35). Other RyR1 binding regions have been proposed for the III-IV loop (3) and 
the carboxyl terminal domain of α1S (11). Even though the latters do not trigger EC coupling per se, a 
recent report indicates that cytoplasmic domains of α1S other than II-III loop affect the magnitude of the 
Ca2+ transients (12). The fact that part of the II-III loop may be anchored to the G region (35) where it 
could interact with β1a may serve as a basis to understand the functional equivalence of the II-III loop 
and β1a and the non-linearity of the EC coupling signaling system noticed previously (38). However, 
specific proposal on the hierarchy of the signals by the II-III loop, β1a, and other regions, cannot be 
specified at this time. Signals generated in separate DHPR domains could converge onto a single RyR1 
domain or separate DHPR domains could activate separate RyR1 domains. The biochemical and 
structural data, taken together with the present data, suggest that many DHPR domains appear to be 
physically docked to RyR1, and that at least two of them, namely the α1S II-III loop and β1a, might be 
responsible for transmission of the EC coupling signal to RyR1. 
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FIGURE LEGENDS 
 
Figure 1. Mapping of DHPR β binding to the G region (residues 3201-3661) of RyR1. A) Library of 
RyR1 fragments used for mapping the β1a binding region. A:1-526, B: 527-1021, C: 1022-1631, D: 
1632-2169, E: 2170-2697, F: 2698-3200, G: 3201-3661, H: 3662-4244, I: 4023-5037.  B) Purified 
recombinant GST-his and GST-β1a-his proteins on a SDS-PAGE (15%) gel stained with Coomassie 
blue. C) Autoradiograms of in-vitro translated RyR1 fragments; RyR1 fragments pulled down by GST-
his protein; and RyR1 fragments pulled down by purified GST-β1a-his protein. D) Autoradiograms of 
in-vitro translated overlapping fragments in the F through H region. F: 2698-3200, FG’: 2894-3356, 
FG’’: 3048-3508, G: 3201-3661, GH’: 3509-3969, H: 3662-4244; and RyR1 fragments pulled down by 
purified GST-β1a-his protein. E) Coomassie-blue stained SDS-PAGE shows pull-down of purified 
skeletal muscle tetrameric RyR1 with GS/GST-β1a-his beads.  
 
Figure 2. Charged residues in the 3490-3523 region of RyR1 diminish binding to DHPR β1a. A) 
Mutations examined in fragment G as follows. PtoA: P3292PPALPAGAPPP3303 to 
A3292AAAAAAAAAAA3303; Δ1: Δ(R3364-E3388); Δ2: Δ(S3399-W3423); Δ3: Δ(A3431-E3455); Δ4: Δ(D3490-
N3523); Δ5: Δ(Q3530-L3559); KtoQ: K3495KKRRGDR3502 to Q3495QQQQGDQ3502; ΔKtoR: Δ(K3495-R3499); 
EtoQ: P3580GREEDADDP3589 to A3580ARQQQAQQL3589. B) Upper panel: autoradiogram of in-vitro 
translated fragment G mutants. Lower panel: fragment G mutants pulled down by GST-β1a-his. Arrows 
indicate Δ4, KtoQ and ΔKtoR. The amount of KtoQ and ΔKtoR represent respectively 15 and 36% of 
the input indicating an approximate 6.5 and 3 folds decrease of pull down efficiency compared to wild-
type G fragment (WT).  
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Figure 3. Ca2+ currents are weakly affected by mutations in RyR1 that diminish binding to DHPR 
β1a. Panels show data from dyspedic myotubes transfected with RyR1 WT (left), RyR1 KtoQ (middle) 
and RyR1 ΔKtoR (right). In black are typical Ca2+ currents at –30 mV and +30 mV for a depolarization 
of 500 ms from a holding potential of –40 mV. In grey are Ca2+ currents in the same conditions with  
10-4 M CdCl2 in the external solution. Ca2+ currents at the end of the depolarization are plotted as a 
function of voltage for the case of myotubes in external solution (black) and external solution with  
10-4 M CdCl2 (grey). A Boltzmann fit of the voltage dependence of the Ca2+ conductance is shown by 
the black line in the bottom graphs. The segmented line repeats the fit of myotubes transfected with 
RyR1 WT for reference. The Boltzmann fit produced the following averages (mean±SE) for Gmax in 
pS/pF units, V1/2 in mV, and k in mV, respectively; for RyR1 WT myotubes, 120.4±9.3, 15.3±1.7, 
4.8±0.5 (n=14); for RyR1 KtoQ myotubes, 114.8±9.1, 9.2±1.5, 8.8±1.5 (n=11); for RyR1 ΔKtoR 
myotubes: 89.1±7.9, 19.7±1.2, 5.7±0.2 (n=20).  
 
Figure 4. Ca2+ transients are strongly affected by mutations in RyR1 that diminish binding to 
DHPR β1a. A) The spatial integral of the confocal fluo-4 fluorescence following fast perfusion of a 
myotube with 0.5 mM 4-CMC present in external solution. The line diagrams with the square pulse 
indicate the time of perfusion (4 seconds). The dotted line in the left panel shows the time course of 
fluo-4 fluorescence in a non-transfected myotube perfused with the 4-CMC solution. B) Histograms of 
the Ca2+ transients elicited by 4-CMC perfusion for non-transfected dyspedic myotubes (NT), and 
dyspedic myotubes transfected with WT RyR1 and RyR1 carrying the KtoQ and ΔKtoR mutations. The 
number of myotubes is indicated in brackets. The averages (mean±SE) for peak fluorescence in ΔF/F 
unit are: for NT myotubes, 0.40±0.08 (n=8); for RyR1 WT myotubes, 6.32±0.87 (n=22); for RyR1 KtoQ 
myotubes, 6.45±0.53 (n=31); for RyR1 ΔKtoR myotubes, 6.34±0.53 (n=32). C) Representative Ca2+ 
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transient traces produced by depolarization to +30 mV from a holding potential of –40 mV, in the 
presence (gray) and absence (black) of 10-4 M CdCl2 in the external solution. The line diagrams with the 
square pulse indicate the duration of the depolarization (50 ms). Only part of the traces (100-250 ms) is 
shown. Note the pulses start from 110 ms. D) Voltage dependence of the peak fluorescence in the 
presence (gray) and absence (black) of Cd2+. A Boltzmann fit produced the following averages 
(mean±SE) values of ΔF/Fmax in ΔF/F units, V1/2 in mV, and k in mV, respectively: for RyR1 WT 
myotubes in external solution: 2.0±0.2, 2.6±1.5, 6.4±0.7 (n=14); for RyR1 WT myotubes in external 
solution with Cd2+: 1.6±0.2, 4.9±1.1, 6.6±0.6 (n=15); for RyR1 KtoQ myotubes in external solution: 
1.1±0.2, 11.7±3.3, 13.2±1.6 (n=13); for RyR1 KtoQ myotubes in external solution with Cd2+: 0.8±0.1, 
8.6±3.9, 10.0±3.1 (n=8); for RyR1 ΔKtoR myotubes in external solution: 1.0±0.1, 19.0±4.9, 14.2±2.4 
(n=10); for RyR1 ΔKtoR myotubes in external solution with Cd2+: 1.1±0.1, 17.3±2.8, 11.7±1.1 (n=11). 
E) Histograms of the initial Ca2+ release rate in myotubes expressing RyR1 WT and mutants.  
The Ca2+ transient traces at +30 mV (in the absence of Cd2+) are analyzed as described in Materials and 
Methods. The histograms show the maximum first derivatives from 90 to 160 ms, with 2 ms interval for 
the interpolation. The number of myotubes is indicated in brackets. The averages (mean±SE) values of 
the maximum Ca2+ transient release rate in Δ(ΔF/F)/ms unit are: for RyR1 WT myotubes, 0.099±0.009 
(n=14); for RyR1 KtoQ myotubes, 0.046±0.007 (n=13); for RyR1 ΔKtoR myotubes, 0.036±0.006 
(n=10).  




